XTTRIUM
SpecialtyXTTRIUM is a specialty pharmaceutical company focused on Dermatology.
XTTRIUM's Key Drugs
XTTRIUM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
XTTRIUM's Recent FDA Approvals
New NDA/BLA approvals for XTTRIUM over the last two years — novel drugs only, excluding generics and label supplements.
XTTRIUM's Therapeutic Areas
XTTRIUM's approved drugs and pipeline span 1 therapeutic area, led by Dermatology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
XTTRIUM's Top Competitors
XTTRIUM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
XTTRIUM Pipeline Snapshot
Active clinical trials for XTTRIUM across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1984-12-24
- Latest
- 2026-02-03
- Applications
- 9